Clinical significance of low-positive troponin I by AxSYM and ACS

180

Jr Lewis, J. F. Taylor, A. Z. Miklos, K. S. Virgo, Michael Creer, D. G. Ritter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We compared troponin I (TnI) assays (AxSYM [Abbott]; ACS:180 [Bayer]) in blood samples with concentrations less than 10 ng/mL (<10 μg/L). Discordant results were evaluated by linearity studies and by testing for rheumatoid factor. Patients with discordant TnI results were compared with patients with concordant results and patients with negative TnI who had a new myocardial infarction or died within 2 months of initial testing. Positive TnI cutoffs by AxSYM and ACS:180 were 0.7 ng/mL (0.7 μg/L) and 0.13 ng/mL (0.13 μg/L), respectively. We identified 173 specimens that were repeatedly positive by at least 1 assay; 143 specimens were positive by both assays. Twenty samples positive for TnI by AxSYM were negative by ACS: 180, while 10 samples positive by ACS:180 were negative by AxSYM. The discordant samples showed no evidence of interfering substances, including rheumatoid factor. Clinical follow-up showed that 26% of patients with elevated TnI by both assays, 33% with TnI positive only by AxSYM, 22% with TnI positive only by ACS:180, and 8% with negative TnI by AxSYM encountered at least 1 clinical end point. Variable detection rates by these assays for low-positive TnI represent a clinically significant problem.

Original languageEnglish (US)
Pages (from-to)396-402
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume116
Issue number3
DOIs
StatePublished - Sep 27 2001

Fingerprint

Troponin I
Rheumatoid Factor
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Lewis, Jr ; Taylor, J. F. ; Miklos, A. Z. ; Virgo, K. S. ; Creer, Michael ; Ritter, D. G. / Clinical significance of low-positive troponin I by AxSYM and ACS : 180. In: American Journal of Clinical Pathology. 2001 ; Vol. 116, No. 3. pp. 396-402.
@article{63e7c08f95694a7591c5cb6cdcb3091e,
title = "Clinical significance of low-positive troponin I by AxSYM and ACS: 180",
abstract = "We compared troponin I (TnI) assays (AxSYM [Abbott]; ACS:180 [Bayer]) in blood samples with concentrations less than 10 ng/mL (<10 μg/L). Discordant results were evaluated by linearity studies and by testing for rheumatoid factor. Patients with discordant TnI results were compared with patients with concordant results and patients with negative TnI who had a new myocardial infarction or died within 2 months of initial testing. Positive TnI cutoffs by AxSYM and ACS:180 were 0.7 ng/mL (0.7 μg/L) and 0.13 ng/mL (0.13 μg/L), respectively. We identified 173 specimens that were repeatedly positive by at least 1 assay; 143 specimens were positive by both assays. Twenty samples positive for TnI by AxSYM were negative by ACS: 180, while 10 samples positive by ACS:180 were negative by AxSYM. The discordant samples showed no evidence of interfering substances, including rheumatoid factor. Clinical follow-up showed that 26{\%} of patients with elevated TnI by both assays, 33{\%} with TnI positive only by AxSYM, 22{\%} with TnI positive only by ACS:180, and 8{\%} with negative TnI by AxSYM encountered at least 1 clinical end point. Variable detection rates by these assays for low-positive TnI represent a clinically significant problem.",
author = "Jr Lewis and Taylor, {J. F.} and Miklos, {A. Z.} and Virgo, {K. S.} and Michael Creer and Ritter, {D. G.}",
year = "2001",
month = "9",
day = "27",
doi = "10.1309/EHMY-7WU1-UYE7-EE99",
language = "English (US)",
volume = "116",
pages = "396--402",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

Clinical significance of low-positive troponin I by AxSYM and ACS : 180. / Lewis, Jr; Taylor, J. F.; Miklos, A. Z.; Virgo, K. S.; Creer, Michael; Ritter, D. G.

In: American Journal of Clinical Pathology, Vol. 116, No. 3, 27.09.2001, p. 396-402.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical significance of low-positive troponin I by AxSYM and ACS

T2 - 180

AU - Lewis, Jr

AU - Taylor, J. F.

AU - Miklos, A. Z.

AU - Virgo, K. S.

AU - Creer, Michael

AU - Ritter, D. G.

PY - 2001/9/27

Y1 - 2001/9/27

N2 - We compared troponin I (TnI) assays (AxSYM [Abbott]; ACS:180 [Bayer]) in blood samples with concentrations less than 10 ng/mL (<10 μg/L). Discordant results were evaluated by linearity studies and by testing for rheumatoid factor. Patients with discordant TnI results were compared with patients with concordant results and patients with negative TnI who had a new myocardial infarction or died within 2 months of initial testing. Positive TnI cutoffs by AxSYM and ACS:180 were 0.7 ng/mL (0.7 μg/L) and 0.13 ng/mL (0.13 μg/L), respectively. We identified 173 specimens that were repeatedly positive by at least 1 assay; 143 specimens were positive by both assays. Twenty samples positive for TnI by AxSYM were negative by ACS: 180, while 10 samples positive by ACS:180 were negative by AxSYM. The discordant samples showed no evidence of interfering substances, including rheumatoid factor. Clinical follow-up showed that 26% of patients with elevated TnI by both assays, 33% with TnI positive only by AxSYM, 22% with TnI positive only by ACS:180, and 8% with negative TnI by AxSYM encountered at least 1 clinical end point. Variable detection rates by these assays for low-positive TnI represent a clinically significant problem.

AB - We compared troponin I (TnI) assays (AxSYM [Abbott]; ACS:180 [Bayer]) in blood samples with concentrations less than 10 ng/mL (<10 μg/L). Discordant results were evaluated by linearity studies and by testing for rheumatoid factor. Patients with discordant TnI results were compared with patients with concordant results and patients with negative TnI who had a new myocardial infarction or died within 2 months of initial testing. Positive TnI cutoffs by AxSYM and ACS:180 were 0.7 ng/mL (0.7 μg/L) and 0.13 ng/mL (0.13 μg/L), respectively. We identified 173 specimens that were repeatedly positive by at least 1 assay; 143 specimens were positive by both assays. Twenty samples positive for TnI by AxSYM were negative by ACS: 180, while 10 samples positive by ACS:180 were negative by AxSYM. The discordant samples showed no evidence of interfering substances, including rheumatoid factor. Clinical follow-up showed that 26% of patients with elevated TnI by both assays, 33% with TnI positive only by AxSYM, 22% with TnI positive only by ACS:180, and 8% with negative TnI by AxSYM encountered at least 1 clinical end point. Variable detection rates by these assays for low-positive TnI represent a clinically significant problem.

UR - http://www.scopus.com/inward/record.url?scp=0034854370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034854370&partnerID=8YFLogxK

U2 - 10.1309/EHMY-7WU1-UYE7-EE99

DO - 10.1309/EHMY-7WU1-UYE7-EE99

M3 - Article

VL - 116

SP - 396

EP - 402

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -